 |
Kekst CNC is handling the Chapter 11 filing of Buffalo-based Athenex Inc., a biopharmaceutical company focused on cancer treatments.
The bankruptcy move, which follows the completion of a strategic review, is designed to facilitate the sale of its primary businesses.
Athenex CEO Johnson Lau said the company sought to be a leader in bringing innovative cancer treatments to the market and improving patient health outcomes.
It succeeded in gaining regulatory approval for tirbanibulin ointment in the US, Taiwan and some EU countries but received a regulatory setback from the US Food and Drug Administration for its oral paclitaxel product.
“This significant regulatory setback coupled with challenging biotech markets and the difficult economic environment, put tremendous pressure on our ability to continue to fund our business,” said Lau.
The company’s manufacturing plant in Clarence, NY, will continue to operate for at least 90 days to provide a supply of tirbanibulin to its commercial customers.
Lau’s goal is to identify purchases who will continue to develop Athenex’s drug candidates.
Kekst CNC’s Daniel Yunger, Wendi Kopsick, Rich Goldman, and Mark Fallati are working the Chapter 11 filing.
Publicis Groupe owns Kekst CNC.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
